Shares of Mallinckrodt PLC (NYSE:MNK) have been given an average rating of “Hold” by the twenty-two research firms that are covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a sell recommendation, fifteen have given a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $28.53.

Several equities analysts recently weighed in on the stock. Cantor Fitzgerald restated a “buy” rating and set a $42.00 target price on shares of Mallinckrodt in a report on Tuesday, August 7th. Piper Jaffray Companies restated a “buy” rating and set a $39.00 target price on shares of Mallinckrodt in a report on Wednesday. Stifel Nicolaus lifted their target price on shares of Mallinckrodt from $18.00 to $30.00 and gave the company a “hold” rating in a report on Wednesday. Raymond James lowered shares of Mallinckrodt from an “outperform” rating to a “market perform” rating and set a $58.00 target price on the stock. in a report on Wednesday. They noted that the move was a valuation call. Finally, BMO Capital Markets restated an “outperform” rating and set a $37.00 target price on shares of Mallinckrodt in a report on Tuesday, August 7th.

Shares of Mallinckrodt traded up $0.40, reaching $31.10, during mid-day trading on Thursday, according to Marketbeat.com. The company had a trading volume of 4,116,910 shares, compared to its average volume of 3,390,203. The firm has a market cap of $2.55 billion, a PE ratio of 4.15, a price-to-earnings-growth ratio of 0.48 and a beta of 1.36. Mallinckrodt has a fifty-two week low of $11.65 and a fifty-two week high of $41.70. The company has a quick ratio of 1.90, a current ratio of 2.27 and a debt-to-equity ratio of 0.98.

Mallinckrodt (NYSE:MNK) last posted its earnings results on Tuesday, August 7th. The company reported $1.78 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.48 by $0.30. The business had revenue of $631.70 million for the quarter, compared to analyst estimates of $621.15 million. Mallinckrodt had a net margin of 59.85% and a return on equity of 10.39%. equities research analysts anticipate that Mallinckrodt will post 6.67 earnings per share for the current year.

In other news, insider Mark Trudeau acquired 3,000 shares of the business’s stock in a transaction on Wednesday, May 16th. The shares were purchased at an average price of $15.54 per share, for a total transaction of $46,620.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 1.80% of the company’s stock.

A number of hedge funds have recently modified their holdings of MNK. Victory Capital Management Inc. acquired a new position in Mallinckrodt in the 1st quarter worth $104,000. Bronfman E.L. Rothschild L.P. lifted its holdings in Mallinckrodt by 11,188.0% in the 1st quarter. Bronfman E.L. Rothschild L.P. now owns 10,385 shares of the company’s stock worth $150,000 after buying an additional 10,293 shares in the last quarter. Virginia Retirement Systems ET AL acquired a new position in Mallinckrodt in the 1st quarter worth $175,000. Financial Gravity Wealth Inc. acquired a new position in Mallinckrodt in the 1st quarter worth $182,000. Finally, Advisors Preferred LLC increased its position in shares of Mallinckrodt by 493.9% in the 2nd quarter. Advisors Preferred LLC now owns 10,512 shares of the company’s stock worth $196,000 after purchasing an additional 8,742 shares during the last quarter.

Mallinckrodt Company Profile

Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.

Featured Story: Trading Strategy Methods for Individual Investors

Analyst Recommendations for Mallinckrodt (NYSE:MNK)

Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.